IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and ...
NIAGARA Phase III trial results show AstraZeneca's IMFINZI (durvalumab) in combination with chemotherapy significantly improves event-free survival (EFS) and overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients, compared to neoadjuvant chemotherapy alone.
Reference News
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and ...
NIAGARA Phase III trial results show AstraZeneca's IMFINZI (durvalumab) in combination with chemotherapy significantly improves event-free survival (EFS) and overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients, compared to neoadjuvant chemotherapy alone.